Jan 11, 2024
Arnon Chait, President and CEO of Cleveland Diagnostics, discusses the role diagnostics play in accurately identifying those patients most at risk for cancer. The current PSA and related tests are used to diagnose prostate cancer to determine if additional diagnostics are necessary. By identifying the stage and treatment options with a more specific blood test and AI-aided identification, doctors and patients can make better informed decisions about further testing or imaging.
Arnon elaborates, "A long time ago, in the late '80s and more in the '90s, a new test called prostate-specific antigen came to the market. It is a simple blood test, which is great and offered a glimpse at the important information for the first time. Before that, it was never available to either a PCP, to a private GP or a urologist, whether you have potentially prostate cancer or not."
"The biggest issue in the industry today, and in the clinical world especially, is what to do with the information. Because some of this information requires downstream diagnostics tests, further diagnostics are highly invasive. So now you ask how accurate they are, and what is the false positive rate? So the key thing to ask always when you have new technology is, what is the cost to the entire system of this technology?"
"We want to find and focus on technology that can look at very, very few markers, but in a correct way. Instead of, for example, looking at DNA, which is information available in your body but is very far from the disease itself. Some of it, namely information in DNA, may say something about cancer but may not. So, it's not that specific."
#ClevelandDiagnostics #CDx #ProstateCancer #ProstateCancerAwareness #IsoPSA #Diagnostics #MedTech
